By Fineline Cube 
China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to jointly develop bispecific antibody drug conjugates (ADCs). The partnership involves an undisclosed amount of upfront payment, milestone payments, and tiered royalties. Adagene will contribute its proprietary antibodies while retaining all rights to these antibodies for non-ADC applications.
Adagene’s Capabilities
Adagene, a clinical-stage biopharma company with platform-driven discovery capabilities, focuses on developing novel antibody-based cancer immunotherapies. Its tripartite platform comprises NEObody, SAFEbody, and POWERbody, along with a unique pipeline addressing unmet needs in oncology.
ConjugateBio’s Expertise
ConjugateBio specializes in developing first-in-class bispecific ADCs for solid tumors. The company leverages third-generation linker-payload technologies to advance its therapeutic candidates.-Fineline Info & Tech